CLINICAL TRIALS PROFILE FOR VIMSELTINIB
✉ Email this page to a colleague
All Clinical Trials for VIMSELTINIB
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05059262 ↗ | Study of Vimseltinib for Tenosynovial Giant Cell Tumor | Recruiting | Deciphera Pharmaceuticals LLC | Phase 3 | 2021-10-14 | This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib. |
| NCT06619561 ↗ | A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | RECRUITING | Deciphera Pharmaceuticals, LLC | PHASE2 | 2024-11-21 | The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years. |
| NCT07158398 ↗ | Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate | NOT_YET_RECRUITING | Deciphera Pharmaceuticals, LLC | PHASE1 | 2025-10-01 | The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days. |
| NCT07158411 ↗ | Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) | NOT_YET_RECRUITING | Deciphera Pharmaceuticals, LLC | PHASE1 | 2025-11-01 | The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VIMSELTINIB
Condition Name
| Condition Name for VIMSELTINIB | |
| Intervention | Trials |
| Healthy Participants | 2 |
| Tenosynovial Giant Cell Tumor, Localized | 1 |
| Chronic Graft-Versus-Host Disease (cGVHD) | 1 |
| Giant Cell Tumor of Tendon Sheath | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for VIMSELTINIB
Trials by Country
Clinical Trial Progress for VIMSELTINIB
Clinical Trial Phase
Clinical Trial Sponsors for VIMSELTINIB
Sponsor Name
